SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
BRIDGEWATER, N.J., March 30, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced the publication of an article that highlights the benefit of diabetes medication delivery devices, including Valeritas’ V-Go® Device, for improving treatment outcomes for patients with diabetes. The review article, “Novel Devices for Delivering Diabetes Medications: Their Value and Some Coverage Considerations,” was published in the March, 2017 issue of Managed Care, vol. 6 (3): 42-45.
The article highlights a number of diabetes medication delivery devices and their impact on treatment outcomes and the healthcare system compared to standard delivery approaches (syringes and pens) and formulations (sub-cutaneous and oral). The author, Bruce W. Sherman, M.D., concluded that, “plan sponsors will benefit from consideration of … drug-delivery devices as part of an expanded approach to effective diabetes management. Inclusion of these offerings as part of the pharmacy benefit may improve adherence because PBMs [pharmacy benefit managers] traditionally focus on medication adherence and may also lower acquisition costs for both patients and plan sponsors.”
“Despite significant resources directed toward diabetes care, including a large number of drug products and managed care programs to improve patient access to medicines, many patients with diabetes still do not reach their treatment goals,” said John Timberlake, President and Chief Executive Officer of Valeritas. “This article reviews how diabetes medication delivery devices, including V-Go Wearable Insulin Delivery Device, improved treatment outcomes and reduced both short-term pharmacy costs and longer-term healthcare costs. We have worked diligently to demonstrate the value of V-Go to patients, their physicians and payers through the execution of numerous clinical studies and we are gratified by the recognition of that work. Diabetes is a costly chronic illness and we will continue to work with payers to adopt V-Go on their pharmacy formulary which will simplify and broaden access to V-Go to improve A1c outcomes at a lower cost to the employers and their insured population.”
Valeritas provided an unrestricted educational grant for preparation of this manuscript.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Forward Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Disposable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group (508)280-6592 [email protected]
